Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724296 | SCV000224481 | pathogenic | not provided | 2014-09-19 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000724296 | SCV004298072 | pathogenic | not provided | 2023-06-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MAFB protein function. ClinVar contains an entry for this variant (Variation ID: 30773). This missense change has been observed in individual(s) with autosomal dominant multicentric carpotarsal osteolysis syndrome (PMID: 22387013, 29120020, 35221875). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 54 of the MAFB protein (p.Ser54Leu). |
OMIM | RCV000023752 | SCV000045043 | pathogenic | Multicentric carpo-tarsal osteolysis with or without nephropathy | 2012-03-09 | no assertion criteria provided | literature only |